The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Silexion Therapeutics Corp’s stock clocked out at $2.36, down -2.48% from its previous closing price of $2.42. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 50889.0 shares were traded. SLXN stock price reached its highest trading level at $2.4399 during the session, while it also had its lowest trading level at $2.275.
Ratios:
To gain a deeper understanding of SLXN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.97 and its Current Ratio is at 3.97. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLXN now has a Market Capitalization of 7378875 and an Enterprise Value of 160875.
Stock Price History:
The Beta on a monthly basis for SLXN is -0.06, which has changed by -0.92732733 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, SLXN has reached a high of $51.75, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is -19.05%, while the 200-Day Moving Average is calculated to be -73.89%.
Shares Statistics:
It appears that SLXN traded 164.65K shares on average per day over the past three months and 42880 shares per day over the past ten days. A total of 3.13M shares are outstanding, with a floating share count of 2.31M. Insiders hold about 26.00% of the company’s shares, while institutions hold 1.14% stake in the company. Shares short for SLXN as of 1764288000 were 112215 with a Short Ratio of 0.48, compared to 1761868800 on 145745. Therefore, it implies a Short% of Shares Outstanding of 112215 and a Short% of Float of 3.63.
Earnings Estimates
The stock of Silexion Therapeutics Corp (SLXN) is currently in the spotlight, with 2.0 analysts actively rating and assessing its market standing.
Analysts are recommending an EPS of between -$3.83 and -$8.24 for the fiscal current year, implying an average EPS of -$6.03. EPS for the following year is -$4.39, with 2.0 analysts recommending between -$3.99 and -$4.8.
